Literature DB >> 10792345

Assessment of disease activity in Graves' ophthalmopathy by orbital ultrasonography and clinical parameters.

M N Gerding1, M F Prummel, W M Wiersinga.   

Abstract

OBJECTIVE: To study if A-mode ultrasonography (US) in combination with the Clinical Activity Score (CAS) and duration of Graves' ophthalmopathy (GO) could predict the response to immunosuppression in Graves' ophthalmopathy.
DESIGN: A prospective clinical study. PATIENTS AND METHODS: Fifty-six consecutive patients with moderately severe GO were treated with retrobulbar irradiation (10 fractions of 2 Gy). Before treatment the internal reflectivity in the extraocular eye muscles, the CAS, and the duration of Graves' ophthalmopathy were assessed and related to the therapeutic outcome 26 weeks after irradiation.
RESULTS: Twenty-eight (50%) of the patients responded favourably to radiotherapy (four patients became worse, and 24 did not change), and the eye muscle echogenecity indeed tended to be lower in the responders than in the non-responders (P = 0.09). From a receiver operator characteristics curve, a cut-off value of 30% yielded a good positive predictive value of 85%, but the negative predictive value was only 60%. The CAS (>/= 4/10) had a positive predictive value of 65%, and a negative predictive value of 56%. When combining the ultrasound with the CAS, the positive predictive value increased to 74% and the negative predictive value to 72%. Adding the duration of eye symptoms (cut-off 18 months), the prediction of response further improved: positive predictive value 79%, and negative predictive value 89%.
CONCLUSIONS: A-mode ultrasonography has a rather good positive predictive value, but its poor negative predictive value precludes its use as sole activity parameter. By adding the Clinical Activity Score and duration of Graves' ophthalmopathy, the negative predictive value increased considerably. By using this combination, inactive disease can be identified more precise, permitting rehabilitative surgery at an earlier stage in these patients.

Entities:  

Mesh:

Year:  2000        PMID: 10792345     DOI: 10.1046/j.1365-2265.2000.00973.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

Review 1.  [Endocrine orbit disorders. Pathogenesis, clinical presentation and examination, stage-dependent therapy].

Authors:  A Eckstein; J Esser
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

2.  [Diagnosis and differential diagnosis of Graves' orbitopathy in MRI].

Authors:  D Daubner; S Spieth; K Engellandt; R von Kummer
Journal:  Radiologe       Date:  2012-06       Impact factor: 0.635

3.  Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.

Authors:  T-C Chang; S-L Liao
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

4.  Update on advanced imaging options for thyroid-associated orbitopathy.

Authors:  Michael P Rabinowitz; Jacqueline R Carrasco
Journal:  Saudi J Ophthalmol       Date:  2012-10

5.  Correlation of signal intensity ratio on orbital MRI-TIRM and clinical activity score as a possible predictor of therapy response in Graves' orbitopathy--a pilot study at 1.5 T.

Authors:  Eberhard C Kirsch; Achim H Kaim; Marion Gregorio De Oliveira; Georg von Arx
Journal:  Neuroradiology       Date:  2009-09-15       Impact factor: 2.804

6.  (99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy (GO).

Authors:  Hua Sun; Xu-Feng Jiang; Shu Wang; Hao-Yan Chen; Jiao Sun; Pei-Yong Li; Guang Ning; Yong-Ju Zhao
Journal:  Endocrine       Date:  2007-06       Impact factor: 3.633

7.  Efficacy of (99m)Tc-EDDA/HYNIC-TOC SPECT/CT scintigraphy in Graves' ophthalmopathy.

Authors:  Rong Zhao; Jiang Wang; Jinglan Deng; Weidong Yang; Jing Wang
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-03-28

8.  Value of Infrared Thermography Camera Attached to a Smartphone for Evaluation and Follow-up of Patients with Graves' Ophthalmopathy.

Authors:  Cínthia Minatel Riguetto; Walter José Minicucci; Arnaldo Moura Neto; Marcos Antonio Tambascia; Denise Engelbrecht Zantut-Wittmann
Journal:  Int J Endocrinol       Date:  2019-05-09       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.